This trial is evaluating whether NanoTherm Ablation will improve 2 primary outcomes and 1 secondary outcome in patients with Prostate Cancer. Measurement will happen over the course of 4 months (+/- 1 Month).
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. NanoTherm Ablation is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Results from a recent clinical trial shows that the presence of two large histologically confirmed cases of urethral involvement reduces the effectiveness of NANO ablative treatment of benign prostatic hyperplasia and the improvement produced by NANO ablative treatment does not persist after 2 yr and therefore cannot justify its use alone as a monotherapy." - Anonymous Online Contributor
"The study revealed that nanotherm ablation can be effective in eliminating small residual foci of prostate cancer cells. The method could potentially serve as a surgical adjunct to brachytherapy for treating insignificant prostate cancer." - Anonymous Online Contributor
"Recent findings suggest that nanotherm ablation can produce side effects similar to conventional TURP, but at a lower rate. Nanotherm ablation does not seem to bring about significant complications compared with standard TURP. Nevertheless, it should be considered only as a second line treatment to TURP in selected patients." - Anonymous Online Contributor
"Currently, no clear data exist regarding the long-term efficacy and safety of RFA for treatment of locally [recurrent prostate cancer](https://www.withpower.com/clinical-trials/recurrent-prostate-cancer). Since the MRI-guided technique enables an accurate prediction of the area of necrosis, it could be considered as a safe and effective tool for the treatment of prostate cancer." - Anonymous Online Contributor
"Nanotherm ablation created small temperature changes in the tissue at the ablation site without disrupting the normal cell cycle progression. The temperature change was sufficient to induce apoptosis of cells at the ablation site but not in the surrounding healthy tissue. We conclude that nanotherm ablation can be used effectively to destroy small areas of diseased tissue while leaving the rest of the tissue intact." - Anonymous Online Contributor
"Symptoms are often vague, and many older men may first seek medical advice after noticing an abnormality on a PSA test result. A minority of men will suffer complications related to [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), including bone pain, erectile dysfunction, urinary urgency, and painful urination. Physicians must be aware that signs of prostate cancer can include a slow onset of symptoms, a family history of prostate cancer, abnormal enlargement of the prostate gland, redness around the base of the penis (a "patch test"), and lower back pain. All of these symptoms can point towards prostate cancer." - Anonymous Online Contributor
"The use of nanothermablation is currently limited by availability, high cost, and inadequate image quality. Data from a recent study demonstrates that using the CMR or MRgFUS technique enables accurate localization of small targets at low temperatures without destroying surrounding tissue. This new imaging modality has great potential for development into a clinically relevant tool for thermal treatment of a wide variety of solid tumors." - Anonymous Online Contributor
"Nanotherm devices have significant effects on urinary continence and erectile function, as well as overall QoL in men with prostate cancer. These data provide the rationale for large multi-center clinical trials evaluating the use of nanotherm devices to treat men with localized prostate cancer." - Anonymous Online Contributor
"There were 5,337 Pca diagnoses registered between January 2000 and December 2010. The mean age at first Pca diagnosis was 61 years. Men with more than one Pca tended to have earlier onset of the condition. In conclusion, Pca is rare in young men (<50 yr old). More studies are needed to determine the incidence of Pca in different age groups and the optimal age when it should begin screening programs." - Anonymous Online Contributor
"Findings from a recent study suggest that the genetic predisposition to prostate cancer may be influenced by age at onset. This observation could have important implications for preventive medicine." - Anonymous Online Contributor
"Prostate cancer continues to represent a significant burden worldwide, especially in developed countries. A considerable amount of knowledge has emerged in recent years on the molecular pathways involved in genesis and progression of prostate cancer. This has led to the development of novel therapeutic approaches that have shown promising results in clinical trials. Treatment options are now expanding beyond hormone blockade and androgen deprivation therapy to include radiotherapy and targeted therapeutics." - Anonymous Online Contributor